中文 | English     

B-hPD-1/hPD-L1 mice

2017-08-04 13:51:07.0

Strain description

Strain NameC57BL/6-Pdcd1tm1(hPDCD1)Cd274tm1(hCD274)/BcgenCommon NameB-hPD-1/hPD-L1 mice
BackgroundC57BL/6Catalog numberB-DM-007
Catalog number (Males)BDM007MCatalog number (Females)BDM007F
Related GenesPD-1(Programmed death-1) ;

PD-L1 (Programmed cell death ligand-1,also known as B7-H1, CD274)


Targeting strategy

打靶策略.png

mRNA expression analysis

图1.png

Fig 1. RT-PCR analysis of the B-hPD-1/hPD-L1 humanized mice.

The splenocytes of the B-hPD-1/hPD-L1 homozygous mice showed expression of human PD-1 and PD-L1 mRNA but not mouse PD-1 and PD-L1 mRNA.


Protein expression analysis

图2.png






Fig 2. Splenocytes from both wild t ype (WT) C57BL/6 and homozygous B-hPD-1/hPD-L1 mice were analyzed by flow  cytometry. 

Mouse PD-L1+ T cells were detected in the WT C57BL/6  mice, while human PD-L1+ T cells were detected in the  homozygous B-hPD-1/hPD-L1 mice.






图3.png






Fig 3. Splenocytes from both wild t ype (WT) C57BL/6 and homozygous B-hPD-1/hPD-L1 mice were analyzed by flow cytometry.

Mouse PD-1+ T cells were detected in the WT C57BL/6 mice, while human PD-1+ T cells were detected in the homozygous B-hPD-1/hPD-L1 mice.




PD-L1(Tecentriq) efficacy evaluation (different doses)

图4.png

Fig 4. Murine colon cancer MC38-hPD-L1 cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1 mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=5). The human PD-L1 antibody Tecentriq significantly inhibited tumor growth, confirming that the B-hPD-1/hPD-L1 mouse model is a powerful tool for in vivo PD-L1 antibody pharmacological efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.


Combination therapy of PD-1(K eytruda) Ab and PD-L1 (T ecentriq) Ab

图5.png

Fig 5. Murine colon cancer MC38-hPD-L1 cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1 mice. Mice were grouped when the tumor size was approximately 150±50 mm3(n=6). Although Keytruda alone gives significant anti-tumor effect, low dose of Tecentriq and the combination of Keytruda and Tecentriq did not show significant difference compared with Keytruda alone at tested condition. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.


Copyright © BIOCYTOGEN LLC. 2017 All Rights Reserved.